Prognostic Role of Serum Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and Nitric Oxide in Patients With Colorectal Carcinoma

Akbulut, Hakan; Altuntaş, Fevzi; Akbulut, K. Gonca; Öztürk, Güler; Cındoruk, Mehmet; Ünal, Ekrem; İçlı, Fikri

doi:10.1006/cyto.2002.1993

Cited by 47 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Measurement of serum VEGF levels was suggested to be useful to evaluate lung cancer progression. Similar data are obtained from studies directed to gastric, colorectal and renal cell carcinomas [17][18][19]. It also seems to be an important determinant in malignnant pleural disease.…”

Section: Discussionsupporting

confidence: 77%

The diagnostic significance and the assessment of the value of vascular endothelial growth factor as a marker for success of chemical pleurodesis in malignant pleural effusion

Kılıç¹,

Fındıkçıoğlu²,

Alver³

et al. 2011

JBiSE

Self Cite

View full text Add to dashboard Cite

Differential diagnosis of pleural effusion is an important issue, since the treatment modalities and prognosis strictly depend on early and correct diagnosis of the underlying etiology. We assessed the efficacy of vascular endothelial growth factor (VEGF) in the differential diagnosis of patients with malignant and non-malignant pleural diseases. And also is assessed of the VEGF as a marker for success of chemical pleurodesis in malignant pleural effusion. Pleural effusions of 40 patients with a mean age of 55 (range, 26 to 78 years) were examined. A total of 20 patients had malignant pleural effusion; malignant meso-thelioma (n = 7), lung cancer (n = 5) and metastatic malignancies (n = 8). Twenty patients had benign pleural effusion; fibrinous pleuritis (n = 6), tubercu-losis (n = 3) empyema (n = 5), congestive heart failure (n = 3), and acute pancreatitis (n = 3). Definitive di-agnosis was obtained in all cases with blind or open pleural biopsy, and cytological examination. VEGF levels were determined by enzyme-linked immu-nosorbent assay. The VEGF level of pleural effusion was comparably higher in the malignant group. The mean level of VEGF in patients with malignant pleu-ral effusions (21.7 ± 1.8 ng/ml) was significantly (P < 0.001) higher than that of (13.2 ± 1.5 ng/ml) non-malignant effusions. No significant difference was found regarding the VEGF levels and histological types in malignant pleural effusions. Negative correlation was observed between success rate of pleurodesis and VEGF level of pleural effusion (p = 0.015). The measurement of VEGF levels in pleural effusion may be useful to differentiate malignant from nonmalignant pleural effusions. VEGF level may also be an important prognostic marker for ef-fective treatment of the patients who had malignant pleural effusions with pleurodesis. It is important issue in here whether VEGF could be useful in prog-nostication of outcome of chemical pleurodesis or not.

show abstract

Section: Discussionsupporting

confidence: 77%

The diagnostic significance and the assessment of the value of vascular endothelial growth factor as a marker for success of chemical pleurodesis in malignant pleural effusion

Kılıç¹,

Fındıkçıoğlu²,

Alver³

et al. 2011

JBiSE

Self Cite

View full text Add to dashboard Cite

show abstract

“…As in many other tumors, several angiogenic regulators have been recognized in colon cancer, including VEGF, PDGF, thrombospondin, and angiopoietins (74,75). Likewise, overexpression of FGF and FGFRs in colon cancer cells and tissues, as well as increase of FGF-2 serum levels in patients with advanced colon cancer, have been extensively reported (76)(77)(78)(79)(80)(81).…”

Section: Angiogenesis In Gastrointestinal Cancersmentioning

confidence: 95%

The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma

Tassi

Wellstein

2006

Seminars in Oncology

View full text Add to dashboard Cite

Tumor angiogenesis has been related to the initiation as well as progression toward more aggressive behavior of human tumors. We will discuss genetic events underlying the initiation and progression of colorectal and pancreatic adenocarcinoma with a particular focus on the modulation of angiogenesis. A secreted fibroblast growth factor (FGF) binding protein (FGF-BP), which is an extracellular chaperone molecule for FGFs, has been shown to enhance FGF-mediated biochemical and biologic events and to be a crucial rate-limiting factor for tumor-dependent angiogenesis. Histochemical and in situ hybridization studies with archival samples show that FGF-BP is induced early during the initiation of colorectal and pancreatic adenocarcinoma. We will discuss the potential of this secreted protein as a serum marker to identify at-risk subjects.

show abstract

“…73 74 In colorectal cancer, bFGF plasma levels were shown to correspond to advanced tumour stages, as well as resistance of tumours to chemotherapy. [75][76][77] Only limited data are available regarding expression of FGFs in gastric and pancreatic carcinoma. Initial results obtained by Tanimoto et al have indicated elevated expression of bFGF mRNA in 55% of gastric carcinoma tissues compared with control tissue.…”

Section: Angiogenic Factorsmentioning

confidence: 99%

Antiangiogenic therapy in human gastrointestinal malignancies

Heidemann

Binion

Domschke

et al. 2006

Gut

View full text Add to dashboard Cite

SUMMARYAngiogenesis is a crucial process involved in numerous physiological and pathophysiological settings. During the past three decades, the field of tumour associated angiogenesis has been the focus of a plethora of basic research projects and clinical studies. Tumour associated neovessels satisfying the increased demand of oxygen and nutrients in malignant tumours are now emerging as specific targets for novel antineoplastic agents. This article discusses the present data on antiangiogenic treatment of human gastrointestinal malignancies, including gastric, pancreatic, and colorectal adenocarcinoma, and outlines potential future perspectives, such as development of surrogate markers of angiogenesis. PROCESS OF TUMOUR ANGIOGENESIS cAngiogenesis, the formation of new vessels from existing capillary beds, represents a central mechanism involved in many physiological and pathophysiological conditions, including embryonal development, wound healing, and chronic inflammation.1 In malignant tumours, angiogenesis represents a prerequisite for tumour growth, as the high metabolism of tumour cells requires large amounts of oxygen and nutrients. Without angiogenesis, the growth of malignant tumours is limited to 1-2 mm in diameter, which corresponds to the maximum distance oxygen can diffuse.2 3 Tumour vascularisation represents a conditio sine qua non for exponential tumour growth. Studies have indicated that the mitotic index of tumour cells decreases with increasing distance from the supplying microvessel.1 3 4 Primary tumours as well as their metastases are dependent on tumour associated microvessels to establish an independent blood supply. Enhanced vascularity allows tumours not only to expand in size but also facilitates haematogenous spreading by a higher probability of tumour angioinvasion. Once deposited in a distant organ, tumour metastases are dependent on building their own microvasculature.6 For this reason, disruption of angiogenesis pathways provides a therapeutic perspective in the treatment of primary malignant human tumours as well as their metastases.The concept that metastases are solely dependent on newly formed blood vessels in order to grow is opposed by observations made by Vermeulen and colleagues.7 According to their findings, approximately one third of hepatic colon cancer metastases studied (n = 28) do not induce new vessels but rather use and preserve the existing abundant vascularisation of the liver parenchyma. This pattern, called ''replacement pattern'', differs from the so-called ''desmoplastic'' and ''pushing''-type of metastasis. In all three patterns of metastasis, overall vessel density was not significantly different. However, a much lower endothelial cell proliferation was encountered in the replacement-type of metastasis. These findings suggest that not counting vessels, but rather evaluating endothelial cell (EC) proliferation, might be the appropriate way for assessing angiogenesis, depending on the type of metastasis.

show abstract

Prognostic Role of Serum Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and Nitric Oxide in Patients With Colorectal Carcinoma

Cited by 47 publications

References 23 publications

The diagnostic significance and the assessment of the value of vascular endothelial growth factor as a marker for success of chemical pleurodesis in malignant pleural effusion

The diagnostic significance and the assessment of the value of vascular endothelial growth factor as a marker for success of chemical pleurodesis in malignant pleural effusion

The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma

Antiangiogenic therapy in human gastrointestinal malignancies

Contact Info

Product

Resources

About